Uniqure N.V. (QURE) — SEC Filings
Uniqure N.V. (QURE) — 44 SEC filings. Latest: 8-K (May 5, 2026). Includes 23 8-K, 7 SC 13G/A, 6 10-Q.
View Uniqure N.V. on SEC EDGAR
Overview
Uniqure N.V. (QURE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 27, 2026: uniQure N.V. filed its Annual Report to Security Holders (ARS) on April 27, 2026, for the period ending December 31, 2025. The filing includes the complete submission text file and the ARS document itself. The company's business and mailing address are located at Paasheuvelweg 25A, Amsterdam, Nether
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Uniqure N.V. is neutral.
Filing Type Overview
Uniqure N.V. (QURE) has filed 23 8-K, 1 ARS, 1 DEFA14A, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of QURE's 31 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $10.41M |
| Net Income | -$161.89M |
| EPS | -$1.38 |
| Debt-to-Equity | 2.88 |
| Cash Position | $597.06M |
| Operating Margin | N/A |
| Total Assets | $888.38M |
| Total Debt | $51.88M |
Key Executives
- Dr. Olav Hellebostad
- Dr. Robert Kotin
- Dr. Olav Hellebø
- Matt Kapusta
- Dr. Ricardo Dolnikoff
- Abigail P. Johnson
Industry Context
uniQure operates in the rapidly evolving gene therapy sector, a field focused on treating rare and devastating diseases with potentially curative single treatments. The industry is characterized by significant scientific innovation, high R&D costs, and a complex regulatory pathway. Competition is intense, with numerous companies, including large pharmaceutical players and emerging biotechs, vying for breakthroughs and market share.
Top Tags
regulatory-filing (7) · 8-K (5) · Biotechnology (4) · financials (4) · 10-Q (4) · sec-filing (3) · Gene Therapy (3) · disclosure (3) · material-definitive-agreement (3) · financial-statements (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $597.06B | Increased from $158.93 million at December 31, 2024, due to financing activities. |
| Net loss (9 months) | $161.89B | Slightly improved from $166.30 million in the prior year period, but still substantial. |
| Follow-on public offering proceeds | $380.74B | Key driver of increased cash and shareholders' equity. |
| R&D expenses (9 months) | $105.89B | Reflects continued significant investment in gene therapy pipeline. |
| Shareholders' equity | $228.75B | Shifted from a deficit of $6.75 million to a positive position. |
| Liability related to pre-funded warrants | $30.72B | New liability recognized from September 2025 public offering. |
| Net loss (3 months) | $80.53B | Widened from $44.38 million in the comparable prior year period. |
| License revenues (9 months) | $10.41B | Increased from $5.18 million in the prior year period, showing some revenue growth. |
| Ordinary shares outstanding | 62,291,663 | As of November 6, 2025, reflecting dilution from offerings. |
| Loss per ordinary share (3 months) | $1.38 | Increased from $0.91 in the prior year period, reflecting higher net loss and share count. |
| Q2 2025 Net Loss | $54.87M | Increased from $48.99M in Q2 2024, indicating widening losses. |
| YTD 2025 Net Loss | $108.97M | Increased from $97.98M in YTD 2024, showing accelerated cash burn. |
| Accumulated Deficit | $1.49B | Grew from $1.38B at year-end 2024, reflecting sustained operational losses. |
| Q2 2025 R&D Expenses | $45.69M | Slight decrease from $46.01M in Q2 2024, but still a major expense. |
| Q2 2025 G&A Expenses | $13.01M | Increased from $11.02M in Q2 2024, contributing to higher overall expenses. |
Forward-Looking Statements
- {"claim":"uniQure N.V.'s stock price may experience downward pressure due to the significant reduction in institutional ownership.","entity":"uniQure N.V.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Uniqure N.V. (QURE)?
Uniqure N.V. has 44 recent SEC filings from Jan 2024 to May 2026, including 23 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of QURE filings?
Across 44 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Uniqure N.V. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Uniqure N.V. (QURE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Uniqure N.V.?
Key financial highlights from Uniqure N.V.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for QURE?
The investment thesis for QURE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Uniqure N.V.?
Key executives identified across Uniqure N.V.'s filings include Dr. Olav Hellebostad, Dr. Robert Kotin, Dr. Olav Hellebø, Matt Kapusta, Dr. Ricardo Dolnikoff and 1 others.
What are the main risk factors for Uniqure N.V. stock?
Of QURE's 31 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Uniqure N.V.?
Recent forward-looking statements from Uniqure N.V. include guidance on {"claim":"uniQure N.V.'s stock price may experience downward pressure due to the significant reduction in institutional .